Steven Paul has had a distinguished career in neuroscience, particularly in CNS drug discovery and development. Dr. Paul is the former President of the Lilly Research Laboratories of Eli Lilly and Company. Prior to his appointment at Weill Cornell, Dr. Paul spent 17-years at Eli Lilly, during which time he held several key leadership roles, including Vice President of Neuroscience (CNS) Research and Group Vice President of Discovery Research (all therapeutic areas). In his most recent role, he was responsible for the company's overall research and development efforts - helping to expand Lilly's R&D efforts in oncology and biotechnology - resulting in a pipeline of approximately 70 new molecular entities. Prior to Lilly, Dr. Paul served as Scientific Director of the National Institute of Mental Health. 

Dr. Paul has been the recipient of many awards and honors and has served on numerous committees and advisory boards. He has also authored or co-authored over 500 papers and book chapters. Dr. Paul is an elected fellow of the American Association for the Advancement of Science and a member of the Institute of Medicine of the National Academy of Sciences. He is also currently on the board of directors or is a trustee of several organizations, including the Sigma-Aldrich Corporation, Alnylam Pharmaceuticals, the Allen Institute for Brain Sciences, The Mind Research Network and the Foundation for the NIH. Dr. Paul has also served as a member of the National Institute of General Medical Sciences (NIGMS) Advisory Council and was appointed by the Secretary of the Department of Health and Human Services (HHS) as a member of the advisory committee to the Director of the NIH from 2001-2006. Dr. Paul is currently a member of the National Advisory Mental Health Council, NIMH, and is board certified by the American Board of Psychiatry and Neurology.

Dr. Paul received his B.A. in Biology and Psychology from Tulane University, and his M.S. and M.D. degrees from the Tulane University School of Medicine.